Article Text

other Versions

Download PDFPDF
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?
  1. Juliana Rodriguez1,2,
  2. David Viveros-Carreño1,3 and
  3. Rene Pareja1,4
  1. 1Department of Gynecologic Oncology, Instituto Nacional de Cancerologia, Bogota, Colombia
  2. 2Department of Gynecology and Obstetrics, section of Gynecologic Oncology, Fundacion Santa Fe de Bogotá, Bogotá, Colombia
  3. 3Gynecologic Oncology, Clínica Universitaria Colombia And Clínica Los Nogales, Bogotá, Colombia
  4. 4Gynecologic Oncology, Clinica Astorga, Medellin, Colombia
  1. Correspondence to Juliana Rodriguez, Department of Gynecologic Oncology, Instituto Nacional de Cancerologia, Bogota, 1 # 9-85, Colombia; julianalrc1106{at}


Cervical cancer is the fourth most common cancer in women worldwide. The preferred treatment for early stage cervical cancer is radical hysterectomy with pelvic lymph node assessment, and adjuvant therapy is suggested according to histopathological risk factors. A landmark study was published in 1999 that established 'intermediate risk' criteria for relapse, showing a benefit in recurrence free rate in patients that received pelvic radiotherapy. Furthermore, in the presence of parametrial, nodal, or vaginal margin involvement, another key study found that the addition of concurrent cisplatin based chemotherapy to radiation therapy improved progression free and overall survival for 'high risk' early cervical cancer. With the advancement in treatment modalities in surgery and radiotherapy, and the improved identification of prognostic histopathological factors, several authors have reconsidered the role of adjuvant therapy after radical hysterectomy in the presence of intermediate risk criteria. Here we review the literature on the evolution of adjuvant therapy for intermediate risk factors.

  • Cervical Cancer
  • Hysterectomy
  • Radiotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Study design, literature acquisition, manuscript writing, and manuscript review: JR, DV-C, and RP.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles